After Monday’s celebrations the sector gets down to discussing the difficult business of actually selling and making money from drugs.
Takeda gave biopharma’s M&A bill a big boost in 2018 but to see just how slow the year was, take a look at deal volumes.
Sanofi has followed a 2015 deal with an €80m stake, joining Lilly and Pfizer as an investor in Biontech.
The New Year is not yet three days old, but deal-hungry investors looking forward to next week’s JP Morgan conference already have a megamerger on their hands.
Shutdown or no, drug reviews are still under way, giving the sector something to look forward to as 2019 kicks off.
Pfizer and Merck & Co take increases, making it easier for others to follow. But shifts in congressional power means pricing will remain a minefield.
Lilly reduces its reliance on older products, but Roche and Sanofi still need fresh blood.
Amarin’s fish oil formulation Vascepa impressed on hard cardiovascular endpoints, but there is confusion about worsening cholesterol in the placebo group.
If big biotech cannot deliver innovation investors might start demanding shareholder payout plans that look more like big pharma's.